Table 1.
Patient characteristics and responses to treatment.
| ID | Sex | Age | Tumor histology | Disease stage | TNM | RT type | Celecoxib dose | Toxicity grade | Response | Status | Time to progression | Site of first recurrence | Survival time (months) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Esophagitis | Pneumonitis | Lung fibrosis | Primary | Nodes | ||||||||||||
| 1 | M | 58 | A | NIB | T4N3M0 | 3D-CRT | 200 | 2 | 3 | 0 | PR | PR | Dl | – | – | 8.5 |
| 2 | M | 55 | Sq | IMA | T3N2M0 | 3D-CRT | 200 | 2 | 1 | 1 | CR | CR | NED | – | – | 59.8 |
| 3 | M | 60 | Sq | MIA | T3N2M0 | 3D-CRT | 200 | 2 | 1 | 1 | CR | CR | Dl | 3.61 | WF 1° tumor | 50.6 |
| 5 | F | 66 | Sq | MB | T2N1M0 | 3D-CRT | 200 | 1 | 2 | 1 | CR | CR | NED | – | – | 60.4 |
| 6 | M | 74 | Sq | IMA | T2N2M0 | 3D-CRT | 200 | 2 | 2 | 1 | PR | CR | DD | 27.8 | WF 1° tumor | 37.5 |
| 8 | M | 49 | A | IMA | T3N2M0 | 3D-CRT | 200 | 2 | 1 | 1 | PR | PR | NED | – | persist. 1° | 57.5 |
| 9 | M | 53 | Sq | 1MB | T4N2M0 | 3D-CRT | 200 | 2 | 1 | 1 | PR | CR | DD | 17.6 | Tumor persist. 1° | 27.8 |
| 10 | F | 53 | NSCNOS | 1MB | T4N2M0 | IMRT | 200 | 2 | 1 | 1 | PR | PR | DD | 11.3 | tumor | 17.3 |
| 11 | F | 65 | A | IMA | T2N2M0 | 3D-CRT | 400 | 2 | 1 | 0 | PR | PR | DD | 4.6 | OF 1° tumor | 14.2 |
| 12 | M | 57 | NSCNOS | IMA | T2N2M0 | IMRT | 400 | 2 | 1 | 1 | CR | CR | Dl | – | – | 50.9 |
| 13* | F | 64 | Sq | 1MB | T4N2M0 | 3D-CRT | 400 | 2 | 1 | 1 | PR | PR | NED | 49.1 | OF LN | 54.6 |
| 14 | M | 67 | NSCNOS | 1MB | T1N3M0 | IMRT | 400 | 1 | 1 | 0 | CR | PR | DD | 1.1 | Brain mets | 7 |
| 15 | F | 42 | Sq | 1MB | T4N3M0 | IMRT | 400 | 0 | 2 | 0 | PR | PR | NED | – | – | 22.7 |
| 16 | F | 67 | Sq | MB | T2N1M0 | IMRT | 400 | 0 | 0 | 1 | CR | CR | NED | – | – | 19.1 |
| 17 | M | 64 | Sq | IMA | T3N2M0 | IMRT | 400 | 1 | 3 | 1 | CR | CR | NED | – | – | 15.5 |
| 18 | M | 68 | Sq | 1MB | T4N2M0 | IMRT | 400 | 1 | 1 | 0 | PR | PR | Dl | – | Adrenal | 8.7 |
| 19 | F | 53 | Sq | 1MB | T4N3M0 | IMRT | 400 | 2 | 1 | 0 | PR | CR | DD | 4 | mets | 7.2 |
| 20 | M | 64 | A | 1MB | T2N3M0 | IMRT | 400 | 2 | 1 | 0 | PR | PR | NED | 0.9 | WF 1° tumor | 13 |
Survival was from date of registration to date of last follow-up or documented death.
*After biopsy-proven recurrence in the supraclavicular region, the patient is currently without evidence of disease.
1°, primary; 3D-CRT, three-dimensional conformal radiation therapy; A, adenocarcinoma; CR, complete response; DD, died of disease; DI, died of other disease; F, female; IMRT, intensity-modulated radiation therapy; LN, lymph node; M, male; NSC NOS, undifferentiated non-small cell carcinoma; OF, out of field; persist., persistent; PR, partial response; RT, radiation therapy; NED, no evidence of disease; Sq, squamous cell carcinoma; WF, within field.